ARTICLE | Clinical News
Novuspharma Phase II cancer results
October 1, 2001 7:00 AM UTC
Novuspharma (NMerc:NOV) said it obtained positive results in a preliminary analysis of an open-label, non-randomized European Phase II clinical study of its lead product BBR 2778 in 33 patients with n...